Teva Pharmaceutical Industries launched its generic version of Forest Laboratories’ Lexapro, for the treatment of depression and generalized anxiety disorder. Teva will enjoy six months of marketing exclusivity, as it was the first company to file an Abbreviated New Drug Application with the FDA. Lexapro has been a major revenue generator for Forest Labs with the product generating sales of $1.8 billion in the first nine months of fiscal 2012. View and share
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli Startup Rings Closing Bell At Nasdaq in NYC
March 28, 2024
Israeli, US Companies Unite To Make More Milk From Mushrooms
March 27, 2024
Facebook comments